Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Announces Preclinical Data Indicating Birinapant's Breadth of Activity in Models of Infectious Disease

MALVERN, Pa., June 9, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced results from its collaboration with the Walter and Eliza Hall Institute of Medical...
May 28, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting

MALVERN, Pa., May 28, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized placebo controlled clinical study of SHAPE...
May 27, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination With Azacitidine in Naive Patients With Higher Risk Myelodysplastic Syndromes (MDS)

MALVERN, Pa., May 27, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that, based upon data from its Phase 1b study of birinapant in combination with...
May 08, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference

MALVERN, Pa., May 8, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Bank...
May 05, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual Society of Investigative Dermatology Meeting

MALVERN, Pa., May 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized, placebo-controlled clinical study of SHAPE...
April 30, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic to Present at the Deutsche Bank 39th Annual Healthcare Conference

MALVERN, Pa., April 30, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...
April 09, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Announces Publication of Structural Characterization of Birinapant

MALVERN, Pa., April 9, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in a forthcoming issue of the Journal of Medicinal Chemistry of...
April 07, 2014 16:05 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc.

SHAPE, a novel, tissue-targeted topical HDAC inhibitor, is expected to enter Phase 2 trials for early-stage CTCL Encouraging responses seen in a randomized Phase 1 trial after only 28 days of...
April 01, 2014 07:00 ET | Source: TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant

MALVERN, Pa., April 1, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further...
March 31, 2014 07:30 ET | Source: TetraLogic Pharmaceuticals

TetraLogic to Present at the 13th Annual Needham Healthcare Conference

MALVERN, Pa., March 31, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right